Kyowa Kirin Co., Ltd. KYKOF
15.90 USD +0.39 (+2.51%)
Nov 10, 2026, 3:50 PM EST
15.90 Day range 15.90
4.20 52-week range 18.00
- YTD
- +0.32%
- 1 year
- +17.08%
- Market cap
- 8.33B
- EPS (ttm)
- 1.01
- P/E ratio
- 15.74
- YTD return
- +0.32%
- 1-year return
- +17.08%
- Volume
- 101
- Avg volume
- 4.22K
- Open
- 15.90
- Previous close
- 15.51
- Day's range
- 15.90 – 15.90
- 52-week range
- 4.20 – 18.00
- Earnings date
- Oct 29, 2026
No chart data for this range yet.
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate 0.2321.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | 0.2321 | — | — | — |
| Aug 3, 2026 | Jun 30, 2026 | 0.2093 | 0.2182 | +0.01 | +4.25% |
| May 7, 2026 | Mar 31, 2026 | 0.173 | 0.1448 | -0.03 | -16.30% |
| Feb 9, 2026 | Dec 31, 2025 | 0.2609 | 0.4198 | +0.16 | +60.90% |
| Oct 30, 2025 | Sep 30, 2025 | 0.2257 | 0.2102 | -0.02 | -6.87% |
| Jul 31, 2025 | Jun 30, 2025 | 0.2209 | 0.1346 | -0.09 | -39.07% |
News
Kyowa Kirin (OTCMKTS:KYKOF) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Analysis 
The XLH Network and Kyowa Kirin Launch the XLH Community Guidebook to Help People Navigate Lifelong Journey with XLH 
Kyowa Kirin to Present New Complementary Evidence Further Defining Clinical Utility of Mogamulizumab in Cutaneous T-Cell Lymphoma at 2026 WCCL 
Kyowa Kirin stops development of skin condition treatment 
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends 
Kyowa Kirin (OTCMKTS:KYKOF) Trading Down 4.5% – Time to Sell? 
Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman 
Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting 
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region 
Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases
Your note
Sign in to keep a note on KYKOF — it syncs with the Stock Master app.